SG Americas Securities LLC Buys New Shares in Acelyrin, Inc. (NASDAQ:SLRN)

SG Americas Securities LLC purchased a new stake in shares of Acelyrin, Inc. (NASDAQ:SLRN) during the fourth quarter, Holdings Channel reports. The fund purchased 14,741 shares of the company’s stock, valued at approximately $110,000.

Other large investors have also recently bought and sold shares of the company. Bank of New York Mellon Corp bought a new stake in shares of Acelyrin during the 2nd quarter valued at about $276,000. Charles Schwab Investment Management Inc. bought a new position in shares of Acelyrin during the 2nd quarter worth approximately $3,328,000. Osaic Holdings Inc. acquired a new stake in shares of Acelyrin during the 2nd quarter worth approximately $25,000. Northern Trust Corp bought a new stake in shares of Acelyrin in the 2nd quarter valued at $1,215,000. Finally, Geode Capital Management LLC acquired a new position in shares of Acelyrin during the 2nd quarter valued at $7,268,000. 87.31% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of equities research analysts have commented on SLRN shares. Wells Fargo & Company raised their price target on shares of Acelyrin from $11.00 to $13.00 and gave the stock an “equal weight” rating in a report on Thursday, March 21st. HC Wainwright restated a “buy” rating and issued a $28.00 target price on shares of Acelyrin in a research note on Monday, April 1st. Three equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $23.67.

Acelyrin Trading Up 2.7 %

Shares of NASDAQ:SLRN opened at $5.01 on Friday. The stock has a market cap of $492.78 million and a PE ratio of -0.47. The stock’s fifty day simple moving average is $7.20 and its two-hundred day simple moving average is $7.80. Acelyrin, Inc. has a 1-year low of $4.74 and a 1-year high of $29.88.

Acelyrin (NASDAQ:SLRN) last released its quarterly earnings results on Thursday, March 28th. The company reported ($0.75) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.00) by $0.25. On average, sell-side analysts forecast that Acelyrin, Inc. will post -4.18 earnings per share for the current fiscal year.

Insider Transactions at Acelyrin

In related news, CEO Shao-Lee Lin sold 15,701 shares of the stock in a transaction that occurred on Tuesday, February 20th. The stock was sold at an average price of $7.60, for a total transaction of $119,327.60. Following the completion of the sale, the chief executive officer now directly owns 1,587,335 shares of the company’s stock, valued at $12,063,746. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.

Acelyrin Profile

Acelyrin, Inc, a clinical biopharma company, focuses on identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The company's lead product candidate is izokibep, a small protein therapeutic designed to inhibit IL-17A with high potency, which is in Phase 3 clinical trials for use in the treatment of Hidradenitis Suppurativa, Psoriatic Arthritis, and uveitis, as well as in Phase 2 clinical trials for use in the treatment of Axial Spondyloarthritis.